⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28782102 | 0.77 | ALDH1A1 (0.68) | — | |
| SCHEMBL21161871 | 0.75 | — | — | |
| SCHEMBL15514664 | 0.75 | — | — | |
| SCHEMBL4669536 | 0.73 | — | — | |
| SCHEMBL29351116 | 0.73 | — | — | |
| SCHEMBL5167521 | 0.73 | CYP3A4 (1.00) | — | |
| SCHEMBL6187 | 0.73 | — | — | |
| SCHEMBL29037263 | 0.72 | CYP3A4 (0.77) | — | |
| SCHEMBL24418727 | 0.71 | — | — | |
| SCHEMBL20333575 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024007520-A1 | ORGANIC COMPOUND AND USE THEREOF | 北京燕化集联光电技术有限公司 | 2024-01-11 | — | — | WO | disclosed |
| EP-4231064-A1 | COMPOSITIONS AND USE THEREOF IN PHOTOELECTRIC FIELD | Zhejiang Brilliant Optoelectronic Technology Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20230167067-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2023-06-01 | — | — | US | disclosed |
| US-11584720-B2 | Photoredox-catalyzed direct C-H functionalization of arenes | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3402799-B1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022079246-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021242955-A1 | FUSED AZOLE HETEROCYCLES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-10988488-B2 | Process for the functionalization of sp2-H carbons using frustrated lewis pair catalysts | UNIVERSITé LAVAL (CA) | 2021-04-27 | — | — | US | disclosed |
| US-10759806-B2 | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2020055113-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2020-03-19 | — | — | WO | disclosed |
| EP-1966158-B1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-8153758-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2012008435-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011097260-A1 | TRIS (ARYLBENZOXAZOLE) BENZENE AND TRIS (ARYLBENZOTHIAZOLE) BENZENE AS ORGANIC ELECTRON - TRANS PORT MATERIALS | NITTO DENKO CORPORATION (JP) | 2011-08-11 | — | — | WO | disclosed |
| US-20100273189-A1 | NON SEPARATION ASSAYS WITH SELECTIVE SIGNAL INHIBITORS | BECKMAN COULTER, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7465795-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| US-7425556-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | disclosed |
| EP-1694659-B1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080194459-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |